Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for CTX-8371 in Cancer, Solid tumor/s. The expected timing is based on the latest available company guidance and may change.
4/16/24- First patient dosed. 11/12/24- Enrollment of 3rd dosing cohort in the coming month. 5/8/25- Evaluating 4th dosing cohort. 8/11/25- DE study data in Q4 2025 & cohort expansion data in 2026. 11/05/25:- New response, no DLTs; Ph1 topline data H1 2026; NSCLC/TNBC cohort expansions start Q4 2025. 03/05/26:- TNBC/NSCLC expansions enrolling; HL cohort to open; initial Ph1/expansion data at major conference in Q2 2026. 05/05/26:- CTX-8371 poster at ASCO 2026; TNBC/NSCLC/HL expansions initiated; additional expansion data expected Q4 2026. 05/21/26:- ASCO 2026 poster shows responses/no DLTs; NSCLC/TNBC/HL expansions started; additional Ph1 data expected Q4 2026. 08/06/26:- Expansions enrolling after ASCO data; additional cohort expansion data expected Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.